Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Environment
InnoCentive Gives Prize4Life Awards
September 3, 2007
| A version of this story appeared in
Volume 85, Issue 36
InnoCentive, a website aimed at researchers who can offer solutions to scientific problems, has awarded five prizes in the first phase of the amyotrophic lateral sclerosis Prize4Life Biomarker Challenge. The winners, three from the U.S. and two from Europe, will each receive $15,000 for their proposals on how to identify an ALS biomarker. Prize4Life, a nonprofit group in Cambridge, Mass., joined with InnoCentive in late 2006 to offer a prize of up to $1 million for the first validated biomarker. The winning proposals came from fields including chemistry, dermatology, cell biology, and biostatistics. The deadline for the challenge's second phase, the submission of actual biomarkers, is Nov. 6, 2008.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter